Briguori Carlo, Focaccio Amelia, D'Amore Carmen, Selvetella Lucio, Lonobile Tommaso
Interventional Cardiology, Clinica Mediterranea, Via Orazio, 2, I-80121, Naples, Italy.
J Invasive Cardiol. 2019 Mar;31(3):52-56. doi: 10.25270/jic/18.00287.
One of the procedural concerns during percutaneous treatment of patients with concomitant coronary artery disease (CAD) and aortic valve stenosis (AS) is the risk of hemodynamic instability. In the present study, we assessed the safety and effectiveness of elective hemodynamic support with the Impella 2.5 system (Abiomed, Inc) in patients undergoing combined high-risk percutaneous coronary intervention (PCI) and balloon aortic valvuloplasty (BAV), as a bridge to transcatheter aortic valve replacement.
Ten patients suffering from acute coronary syndrome (ACS) and severe AS were included. In all patients, we first performed PCI with the hemodynamic support of the Impella 2.5 system, and then BAV.
The Impella catheter was successfully positioned in the left ventricle in all instances. All cases were successful, without any intraprocedural complications. All patients were discharged without any major clinical events.
These preliminary results suggest that elective use of the Impella 2.5 system is safe and effective when performing PCI and BAV in high-risk ACS patients suffering from concomitant severe CAD and AS.
在经皮治疗合并冠状动脉疾病(CAD)和主动脉瓣狭窄(AS)的患者过程中,一个程序上需要关注的问题是血流动力学不稳定的风险。在本研究中,我们评估了在接受高风险经皮冠状动脉介入治疗(PCI)和球囊主动脉瓣成形术(BAV)联合治疗的患者中,使用Impella 2.5系统(Abiomed公司)进行选择性血流动力学支持作为经导管主动脉瓣置换术桥梁的安全性和有效性。
纳入10例患有急性冠状动脉综合征(ACS)和严重AS的患者。在所有患者中,我们首先在Impella 2.5系统的血流动力学支持下进行PCI,然后进行BAV。
在所有情况下,Impella导管均成功置于左心室。所有病例均成功,术中无任何并发症。所有患者均出院,无任何重大临床事件。
这些初步结果表明,在患有合并严重CAD和AS的高风险ACS患者中进行PCI和BAV时,选择性使用Impella 2.5系统是安全有效的。